Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


Biliary tract cancer: current challenges and future prospects.

Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F.

Cancer Manag Res. 2018 Dec 28;11:379-388. doi: 10.2147/CMAR.S157156. eCollection 2019. Review.


A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.

Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A.

Ann Oncol. 2018 Dec 1;29(12):2356-2362. doi: 10.1093/annonc/mdy407.


Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N.

Cell Mol Life Sci. 2018 Nov;75(22):4151-4162. doi: 10.1007/s00018-018-2906-9. Epub 2018 Sep 1. Review.


Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N.

Cancer Discov. 2018 Oct;8(10):1270-1285. doi: 10.1158/2159-8290.CD-17-0891. Epub 2018 Aug 30.


Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F.

Haematologica. 2018 Aug 3. pii: haematol.2018.191684. doi: 10.3324/haematol.2018.191684. [Epub ahead of print]


MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Ghidini M, Hahne JC, Frizziero M, Tomasello G, Trevisani F, Lampis A, Passalacqua R, Valeri N.

Target Oncol. 2018 Aug;13(4):423-436. doi: 10.1007/s11523-018-0580-3.


Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.

Hahne JC, Valeri N.

Front Oncol. 2018 Jun 18;8:226. doi: 10.3389/fonc.2018.00226. eCollection 2018. Review.


Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.


KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.


First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.

Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R.

Oncotarget. 2017 Dec 4;8(67):111795-111806. doi: 10.18632/oncotarget.22909. eCollection 2017 Dec 19.


MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.

Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C.

Gastroenterology. 2018 Mar;154(4):1066-1079.e5. doi: 10.1053/j.gastro.2017.10.043. Epub 2017 Nov 4.


Characterisation of the immune-related transcriptome in resected biliary tract cancers.

Ghidini M, Cascione L, Carotenuto P, Lampis A, Trevisani F, Previdi MC, Hahne JC, Said-Huntingford I, Raj M, Zerbi A, Mescoli C, Cillo U, Rugge M, Roncalli M, Torzilli G, Rimassa L, Santoro A, Valeri N, Fassan M, Braconi C.

Eur J Cancer. 2017 Nov;86:158-165. doi: 10.1016/j.ejca.2017.09.005. Epub 2017 Oct 6.


Clinical development of mTor inhibitors for renal cancer.

Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S.

Expert Opin Investig Drugs. 2017 Nov;26(11):1229-1237. doi: 10.1080/13543784.2017.1384813. Epub 2017 Oct 3. Review.


Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N.

Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8.


Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.

Lote H, Spiteri I, Ermini L, Vatsiou A, Roy A, McDonald A, Maka N, Balsitis M, Bose N, Simbolo M, Mafficini A, Lampis A, Hahne JC, Trevisani F, Eltahir Z, Mentrasti G, Findlay C, Kalkman EAJ, Punta M, Werner B, Lise S, Aktipis A, Maley C, Greaves M, Braconi C, White J, Fassan M, Scarpa A, Sottoriva A, Valeri N.

Ann Oncol. 2017 Jun 1;28(6):1243-1249. doi: 10.1093/annonc/mdx074.


Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.

Ghidini M, Petrelli F, Hahne JC, De Giorgi A, Toppo L, Pizzo C, Ratti M, Barni S, Passalacqua R, Tomasello G.

Med Oncol. 2017 Apr;34(4):62. doi: 10.1007/s12032-017-0919-0. Epub 2017 Mar 18. Review.


MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.

Trevisani F, Ghidini M, Larcher A, Lampis A, Lote H, Manunta P, Alibrandi MT, Zagato L, Citterio L, Dell'Antonio G, Carenzi C, Capasso G, Rugge M, Rigotti P, Bertini R, Cascione L, Briganti A, Salonia A, Benigni F, Braconi C, Fassan M, Hahne JC, Montorsi F, Valeri N.

Br J Cancer. 2016 Nov 22;115(11):1343-1350. doi: 10.1038/bjc.2016.329. Epub 2016 Nov 1.


Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.

Carotenuto P, Fassan M, Pandolfo R, Lampis A, Vicentini C, Cascione L, Paulus-Hock V, Boulter L, Guest R, Quagliata L, Hahne JC, Ridgway R, Jamieson T, Athineos D, Veronese A, Visone R, Murgia C, Ferrari G, Guzzardo V, Evans TRJ, MacLeod M, Feng GJ, Dale T, Negrini M, Forbes SJ, Terracciano L, Scarpa A, Patel T, Valeri N, Workman P, Sansom O, Braconi C.

Gut. 2017 Jul;66(7):1268-1277. doi: 10.1136/gutjnl-2016-312278. Epub 2016 Sep 12.


New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim.

Ghidini M, Hahne JC, Trevisani F, Panni S, Ratti M, Toppo L, Tomasello G.

Ther Clin Risk Manag. 2016 Jun 24;12:1009-15. doi: 10.2147/TCRM.S80732. eCollection 2016. Review.


Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Carcinogenesis. 2016 Sep;37(9):852-7. doi: 10.1093/carcin/bgw073. Epub 2016 Jul 5.


Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.


Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.


Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.

Hahne JC, Kurz A, Meyer SR, Dietl J, Engel JB, Honig A.

Arch Gynecol Obstet. 2015 Jan;291(1):131-41. doi: 10.1007/s00404-014-3389-z. Epub 2014 Aug 13.


The effect of Cordyceps extract and a mixture of Ganoderma lucidum/Agaricus Blazi Murill extract on human endometrial cancer cell lines in vitro.

Hahne JC, Meyer SR, Dietl J, Honig A.

Int J Oncol. 2014 Jul;45(1):373-82. doi: 10.3892/ijo.2014.2414. Epub 2014 May 5.


Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Hahne JC, Meyer SR, Kranke P, Dietl J, Guckenberger M, Polat B, Hönig A.

Strahlenther Onkol. 2013 Dec;189(12):1040-8. doi: 10.1007/s00066-013-0434-y. Epub 2013 Oct 16.


Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.

Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.

Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.


Immune escape of AKT overexpressing ovarian cancer cells.

Hahne JC, Meyer SR, Gambaryan S, Walter U, Dietl J, Engel JB, Honig A.

Int J Oncol. 2013 May;42(5):1630-5. doi: 10.3892/ijo.2013.1846. Epub 2013 Mar 4.


Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.

Hahne JC, Schmidt H, Meyer SR, Engel JB, Dietl J, Honig A.

J Cancer Res Clin Oncol. 2013 Jun;139(6):905-14. doi: 10.1007/s00432-013-1399-z. Epub 2013 Feb 26.


Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.

Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, Häussler SF, Segerer SE, Fujita N, Dietl J, Engel JB.

Oncol Rep. 2012 Dec;28(6):2023-8. doi: 10.3892/or.2012.2041. Epub 2012 Sep 18.


Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.

Engel JB, Hahne JC, Häusler SF, Meyer S, Segerer SE, Diessner J, Dietl J, Honig A.

Anticancer Res. 2012 May;32(5):2063-8.


PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.

Honig A, Hahne JC, Meyer S, Kranke P, Häusler S, Diessner J, Dietl J, Engel JB.

Anticancer Res. 2012 May;32(5):2035-41.


Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.

Engel JB, Martens T, Hahne JC, Häusler SF, Krockenberger M, Segerer S, Djakovic A, Meyer S, Dietl J, Wischhusen J, Honig A.

Anticancer Drugs. 2012 Apr;23(4):426-36. doi: 10.1097/CAD.0b013e32834fb8ce.


Evaluation of effects caused by differentially spliced Ets-1 transcripts in fibroblasts.

Hahne JC, Fuchs T, Florin A, Edwards D, Pourtier A, Soncin F, Wernert N.

Int J Oncol. 2011 Nov;39(5):1073-82. doi: 10.3892/ijo.2011.1152. Epub 2011 Aug 9.


Identification of ETS-1 target genes in human fibroblasts.

Hahne JC, Okuducu AF, Fuchs T, Florin A, Wernert N.

Int J Oncol. 2011 Jun;38(6):1645-52. doi: 10.3892/ijo.2011.981. Epub 2011 Mar 21.


Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1.

Hahne JC, Kummer S, Heukamp LC, Fuchs T, Gun M, Langer B, Von Ruecker A, Wernert N.

Int J Oncol. 2009 Nov;35(5):989-96.


Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes.

Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, Mattot V, Pourtier-Manzanedo A, Pietsch T, Fafeur V, Wernert N.

Int J Oncol. 2009 Feb;34(2):377-89.


Outcome of outpatient neurology consultations: physician's evaluations compared to patients' perceptions.

Narayanaswami P, Hahne JC.

J Neurol Sci. 2009 Jan 15;276(1-2):175-8. doi: 10.1016/j.jns.2008.09.036. Epub 2008 Nov 20.


The transcription factor ETS-1: its role in tumour development and strategies for its inhibition.

Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N.

Mini Rev Med Chem. 2008 Oct;8(11):1095-105. Review.


The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.


Tumor-stroma interactions of metastatic prostate cancer cell lines: analyses using microarrays.

Wernert N, Kaminski A, Haddouti el-M, Hahne JC.

Methods Mol Biol. 2007;382:223-37.


Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.

Haas S, Park TW, Hahne JC, Fischer HP.

Virchows Arch. 2008 Mar;452(3):277-83. doi: 10.1007/s00428-007-0563-8.


The Ets-1 transcription factor is involved in pterygial angiogenesis.

Naib-Majani W, Breipohl W, Shazli EE, Theuerkauf I, Pleyer U, Hahne JC, Wernert N.

Anat Histol Embryol. 2007 Apr;36(2):107-10.


Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.

Kaminski A, Hahne JC, Haddouti el-M, Florin A, Wellmann A, Wernert N.

Int J Mol Med. 2006 Nov;18(5):941-50.


Immunohistochemical quantification of lymph vessels, VEGF-C and VEGF receptor 3 in human sarcomas.

Friedrichs N, Hahne JC, Pepper MS, Rommerscheidt-Fuss U, Stelzner F, Buettner R, Wernert N.

Histopathology. 2006 Jul;49(1):87-8. No abstract available.


Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts.

Hahne JC, Fuchs T, El Mustapha H, Okuducu AF, Bories JC, Wernert N.

Int J Mol Med. 2006 Jul;18(1):153-9.


Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer.

Okuducu AF, Janzen V, Ko Y, Hahne JC, Lu H, Ma ZL, Albers P, Sahin A, Wellmann A, Scheinert P, Wernert N.

Int J Oncol. 2005 Nov;27(5):1273-82.


Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth.

Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N.

Oncogene. 2005 Aug 11;24(34):5384-8.


Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay.

Kiriakidis S, Högemeier O, Starcke S, Dombrowski F, Hahne JC, Pepper M, Jha HC, Wernert N.

Br J Nutr. 2005 Mar;93(3):317-23.


Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression.

Sahin A, Velten M, Pietsch T, Knuefermann P, Okuducu AF, Hahne JC, Wernert N.

Int J Mol Med. 2005 May;15(5):771-6.


Laser-assisted microdissection, techniques and applications in pathology (review).

Okuducu AF, Hahne JC, Von Deimling A, Wernert N.

Int J Mol Med. 2005 May;15(5):763-9. Review.


Supplemental Content

Loading ...
Support Center